Research · head to head
Dotmatics vs Form Bio
Dotmatics
Research
Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens
- From
- On request
- Rated
- -
Form Bio
Research
Computational platform for cell and gene therapy design and manufacturability
- From
- On request
- Rated
- -
The short version
- Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
- They diverge on capability: Dotmatics covers Dotmatics platform, Form Bio covers FormManufacturing.
- Prices and features above were last checked on 31 August 2026.
Where they differ
Only the attributes on which Dotmatics and Form Bio actually diverge.
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in Dotmatics
- Dotmatics platform
- GraphPad Prism
- SnapGene
- Geneious Prime and Biologics
- LabArchives
- Flow cytometry tools
- Protein Metrics
- Siemens ownership
Only in Form Bio
- FormManufacturing
- Payload design optimisation
- Genome integrity analysis
- Manufacturability prediction
- In silico workflows
- Scale-up monitoring
- Cell and gene therapy focus
- Collaboration
What people use each for
The jobs each tool is most often brought in to do.
Dotmatics
- A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot Form Bio
- A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot Form Bio
- A university licensing LabArchives across departments as an institutional electronic lab notebooknot Form Bio
- A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot Form Bio
Form Bio
- A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Dotmatics
- A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Dotmatics
- A CDMO characterising what a client construct actually produces against what was specifiednot Dotmatics
- A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Dotmatics
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
Dotmatics
- The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
- The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
- Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
- Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
- Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.
Form Bio
- The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
- The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
- No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
- This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
- Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.
Pricing, plan by plan
Dotmatics
On request- Dotmatics platform$undefined/year
- Enterprise informatics platform priced per user per year on quotation
- Chemistry and biology registration, assay data and ELN modules scoped separately
- Implementation and data migration services quoted as a separate programme
Form Bio
On request- FormManufacturing$undefined/year
- Pricing only through a sales process
- Scoped per therapeutic programme rather than per seat
- AAV-focused offering at launch
Which should you pick?
Choose Dotmatics if
- You need dotmatics platform.
- You work on Web, Windows, macOS, On-premise.
- You also want graphpad prism.
Choose Form Bio if
- You need formmanufacturing.
- You work on Web, Cloud.
- You also want payload design optimisation.
Questions people ask
- Is Dotmatics or Form Bio better?
- Neither clearly leads. Dotmatics starts at On request and Form Bio at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, Dotmatics or Form Bio?
- Dotmatics starts at On request and Form Bio at On request.
- Does Dotmatics or Form Bio run on more platforms?
- Dotmatics runs on Web, Windows, macOS, On-premise. Form Bio runs on Web, Cloud.
- What is Dotmatics best used for?
- Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what Form Bio is typically brought in for.
- What can Dotmatics do that Form Bio cannot?
- Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction.
Answered from the vendors’ own pages
Dotmatics: Who owns Dotmatics?
Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.
Form Bio: What does Form Bio sell now?
FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.
Dotmatics: Is GraphPad Prism a Dotmatics product?
Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.
Form Bio: Is it still a general bioinformatics platform?
No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.
Dotmatics: Do the products work together?
To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.
Form Bio: Where did the company come from?
It spun out of Colossal Biosciences in 2022.
Dotmatics: Is enterprise pricing published?
No. The informatics platform is quoted per user per year with modules and services scoped separately.
Form Bio: Is pricing published?
No. Engagements are scoped per programme through a sales process.
Related pages
Other head to heads
- Dotmatics vs LabArchives
- Dotmatics vs Benchling
- Dotmatics vs Sapio Sciences
- Dotmatics vs Labguru
- Dotmatics vs LabVantage
- Dotmatics vs Chemaxon
- Dotmatics vs OpenEye, Cadence Molecular Sciences
- Dotmatics vs Schrodinger
- Dotmatics vs DNAnexus
- Dotmatics vs Scispot
- Dotmatics vs Seven Bridges
- Dotmatics vs Castor EDC
- Dotmatics vs Condens
- Dotmatics vs Florence eBinders
- Dotmatics vs Terra
- Dotmatics vs Mouseflow
- Dotmatics vs Obsidian
- Dotmatics vs Paperpile
- Dotmatics vs Reduct
- Dotmatics vs Remesh
- Form Bio vs LabArchives
- Form Bio vs Benchling
- Form Bio vs Sapio Sciences
- Form Bio vs Labguru
- Form Bio vs LabVantage
- Form Bio vs Chemaxon
- Form Bio vs OpenEye, Cadence Molecular Sciences
- Form Bio vs Schrodinger
- Form Bio vs DNAnexus
- Form Bio vs Scispot
- Form Bio vs Seven Bridges
- Form Bio vs Castor EDC
- Form Bio vs Condens
- Form Bio vs Florence eBinders
- Form Bio vs Terra
- Form Bio vs Mouseflow
- Form Bio vs Obsidian
- Form Bio vs Paperpile
- Form Bio vs Reduct
- Form Bio vs Remesh